Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review
Authors:
Open Access
- 1 January 2018
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 51 (8) , e7440
Abstract
Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies.Keywords
This publication has 53 references indexed in Scilit:
- Strontium ranelate prevents radiological progression in patients with primary knee osteoarthritis: a responders analysisOsteoarthritis and Cartilage, 2013
- Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trialAnnals of the Rheumatic Diseases, 2013
- Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis modelActa Pharmacologica Sinica, 2013
- American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 2012
- Productivity costs and medical costs among working patients with knee osteoarthritisArthritis Care & Research, 2012
- Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosisOsteoporosis International, 2011
- Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritisClimacteric, 2010
- Evidence-Based Practice, Step by Step: Asking the Clinical QuestionAJN, American Journal of Nursing, 2010
- Osteoblasts play key roles in the mechanisms of action of strontium ranelateBritish Journal of Pharmacology, 2009
- Effects of strontium ranelate on spinal osteoarthritis progressionAnnals of the Rheumatic Diseases, 2008